BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386-388. [PMID: 19274799 DOI: 10.1097/mpg.0b013e3181957a11] [Cited by in Crossref: 90] [Cited by in F6Publishing: 29] [Article Influence: 6.9] [Reference Citation Analysis]
Number Citing Articles
1 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol 2012; 18(35): 4823-4854 [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
2 Kelsen J, Dige A, Christensen M, D'Amore F, Iversen L. Frequency and clonality of peripheral γδ T cells in psoriasis patients receiving anti-tumour necrosis factor-α therapy. Clin Exp Immunol 2014;177:142-8. [PMID: 24635218 DOI: 10.1111/cei.12331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Ye J, Erland LAE, Gill SK, Bishop SL, Verdugo-Meza A, Murch SJ, Gibson DL. Metabolomics-Guided Hypothesis Generation for Mechanisms of Intestinal Protection by Live Biotherapeutic Products. Biomolecules 2021;11:738. [PMID: 34063522 DOI: 10.3390/biom11050738] [Reference Citation Analysis]
4 Buchner AM, Blonski W, Lichtenstein GR. Update on the management of Crohn‘s disease. Curr Gastroenterol Rep. 2011;13:465-474. [PMID: 21792543 DOI: 10.1007/s11894-011-0220-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
5 Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient 2013;6:241-55. [PMID: 24127239 DOI: 10.1007/s40271-013-0031-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
6 Llanos-Chea A, Shapiro JM, Winter RW, Jerger L, Menz T, Gibson M, Friedmann AM, Treaba D, Papamichael K, Cheifetz AS, Friedman S, Hamilton MJ, Winter HS. Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. Dig Dis Sci 2021. [PMID: 33595782 DOI: 10.1007/s10620-021-06884-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yang J, Wu SJ, Dai WT, Li YX, Li YY. The human disease network in terms of dysfunctional regulatory mechanisms. Biol Direct 2015;10:60. [PMID: 26450611 DOI: 10.1186/s13062-015-0088-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
8 Wiksyk B, Joe H, Fenton D, Kelly JK, Truong PT. Resolution of Metastatic Colon Cancer upon Withdrawal of Anti-TNF Therapy for Crohn's Disease. J Gastrointest Cancer 2019;50:665-7. [PMID: 29682686 DOI: 10.1007/s12029-018-0107-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626 [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
10 Mizukami T, Obara M, Nishikomori R, Kawai T, Tahara Y, Sameshima N, Marutsuka K, Nakase H, Kimura N, Heike T, Nunoi H. Successful treatment with infliximab for inflammatory colitis in a patient with X-linked anhidrotic ectodermal dysplasia with immunodeficiency. J Clin Immunol. 2012;32:39-49. [PMID: 21993693 DOI: 10.1007/s10875-011-9600-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
11 Selvaraj SA, Chairez E, Wilson LM, Lazarev M, Bass EB, Hutfless S. Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and hepatosplenic T-cell lymphoma. Syst Rev. 2013;2:53. [PMID: 23826928 DOI: 10.1186/2046-4053-2-53] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
12 Nguyen DL, Palmer LB, Nguyen ET, McClave SA, Martindale RG, Bechtold ML. Specialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis. Therap Adv Gastroenterol 2015;8:168-75. [PMID: 26136834 DOI: 10.1177/1756283X15578607] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 6.4] [Reference Citation Analysis]
13 Rider P, Carmi Y, Cohen I. Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations. Int J Cell Biol 2016;2016:9259646. [PMID: 28083070 DOI: 10.1155/2016/9259646] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 15.8] [Reference Citation Analysis]
14 Seow CH, de Silva S, Kaplan GG, Devlin SM, Ghosh S, Panaccione R. Managing the risks of IBD therapy. Curr Gastroenterol Rep 2009;11:509-17. [PMID: 19903428 DOI: 10.1007/s11894-009-0077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
15 Herrinton LJ, Liu L, Abramson O, Jaffe ES. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. Pharmacoepidemiol Drug Saf. 2012;21:49-52. [PMID: 21823196 DOI: 10.1002/pds.2216] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
16 Kamata N, Oshitani N, Watanabe K, Watanabe K, Hosomi S, Noguchi A, Yukawa T, Yamagami H, Shiba M, Tanigawa T, Watanabe T, Tominaga K, Fujiwara Y, Arakawa T. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response. Dig Dis Sci 2015;60:1382-8. [PMID: 25532505 DOI: 10.1007/s10620-014-3493-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
17 Kelsen J, Dige A, Schwindt H, D'Amore F, Pedersen FS, Agnholt J, Christensen LA, Dahlerup JF, Hvas CL. Infliximab induces clonal expansion of γδ-T cells in Crohn's disease: a predictor of lymphoma risk? PLoS One 2011;6:e17890. [PMID: 21483853 DOI: 10.1371/journal.pone.0017890] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
18 Nattiv R, Wojcicki JM, Garnett EA, Gupta N, Heyman MB. High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice. World J Gastroenterol 2012; 18(11): 1229-1234 [PMID: 22468086 DOI: 10.3748/wjg.v18.i11.1229] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
19 Gómez-García M, Cabello-Tapia MJ, Sánchez-Capilla AD, Teresa-Galván JD, Redondo-Cerezo E. Thiopurines related malignancies in inflammatory bowel disease: Local experience in Granada, Spain. World J Gastroenterol 2013; 19(30): 4877-4886 [PMID: 23946592 DOI: 10.3748/wjg.v19.i30.4877] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
20 Shah ED, Coburn ES, Nayyar A, Lee KJ, Koliani-Pace JL, Siegel CA. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther 2020;51:527-33. [PMID: 31990422 DOI: 10.1111/apt.15637] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
21 Hirai F, Ishihara H, Yada S, Esaki M, Ohwan T, Nozaki R, Ashizuka S, Inatsu H, Ohi H, Aoyagi K, Mizuta Y, Matsumoto T, Matsui T. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults. Dig Dis Sci 2013;58:1329-34. [PMID: 22926500 DOI: 10.1007/s10620-012-2374-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
22 Horneff G, Hospach T, Dannecker G, Föll D, Haas JP, Girschick HJ, Huppertz HI, Keitzer R, Laws HJ, Michels H, Minden K, Trauzeddel R. [Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009]. Z Rheumatol 2010;69:561-7. [PMID: 20174926 DOI: 10.1007/s00393-009-0600-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Théophile H, Schaeverbeke T, Miremont-Salamé G, Abouelfath A, Kahn V, Haramburu F, Bégaud B. Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system. Drug Saf 2011;34:577-85. [PMID: 21663333 DOI: 10.2165/11590200-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 Bewtra M, Newcomb CW, Wu Q, Chen L, Xie F, Roy JA, Aarons CB, Osterman MT, Forde KA, Curtis JR, Lewis JD. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med 2015;163:262-70. [PMID: 26168366 DOI: 10.7326/M14-0960] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
25 Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:621-31. [PMID: 20594135 DOI: 10.1586/eci.10.36] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
26 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Reference Citation Analysis]
27 Song YD, Liu SX, Zhong YQ. Biological agents for treatment of inflammatory bowel disease: Research progress and associated risks. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 2964-2973 [DOI: 10.11569/wcjd.v24.i19.2964] [Reference Citation Analysis]
28 Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, Ibañez P, Juliao F, Kotze PG, Marroquín de la Garza JM, Monreal Robles R, Rocha JL, Steinwurz F, Vázquez-Frías R, Veitia G, Zaltman C. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Rev Gastroenterol Mex 2017;82:134-55. [PMID: 28318706 DOI: 10.1016/j.rgmx.2016.07.005] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Satou A, Tsuzuki T, Nakamura S. Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype. J Clin Exp Hematop 2019;59:56-63. [PMID: 31257346 DOI: 10.3960/jslrt.19013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Arana A, Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation. Drug Saf 2010;33:489-501. [PMID: 20486731 DOI: 10.2165/11532550-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
31 Djurić Z, Šaranac L, Budić I, Pavlović V, Djordjević J. Therapeutic role of methotrexate in pediatric Crohn's disease. Bosn J Basic Med Sci 2018;18:211-6. [PMID: 29338679 DOI: 10.17305/bjbms.2018.2792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]